Quoin Pharmaceuticals Clears FDA Hurdle for Peeling Skin Syndrome Trial — Quoin Pharmaceuticals, Ltd.

Event summary

Quoin Pharmaceuticals received FDA IND clearance to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome (PSS) on July 9, 2026.
The study plans to enroll 6-8 pediatric and adult patients in the U.S. and Europe, with initiation expected in the second half of 2026.
This is the first-ever formal clinical study for a potential PSS therapy and the second IND cleared indication for QRX003, following Netherton Syndrome.
The FDA expressed no safety concerns over the study design and duration of dosing.

The big picture

Quoin Pharmaceuticals is expanding its focus on rare dermatologic diseases with the initiation of a Phase 2 trial for Peeling Skin Syndrome, following its work in Netherton Syndrome. This move underscores the company's strategy to target underserved patient populations in the orphan drug space, where regulatory pathways are often accelerated and market exclusivity can be substantial. The clearance from the FDA highlights the growing interest in developing treatments for rare skin conditions that have historically been overlooked.

What we're watching

Clinical Progress: Whether the Phase 2 study of QRX003 in PSS will demonstrate efficacy and safety, paving the way for further development.
Regulatory Strategy: How Quoin aligns with the FDA for its upcoming Phase 3 study in Netherton Syndrome, given the positive feedback on the PSS trial design.
Pipeline Expansion: The pace at which Quoin advances QRX003 into additional ichthyosis indications where no approved treatments exist.